The stock has a 36-month beta value of 2.48. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SGMT is 21.13M, and at present, short sellers hold a 19.74% of that float. On November 15, 2024, the average trading volume of SGMT was 1.42M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SGMT) stock’s latest price update
The stock of Sagimet Biosciences Inc (NASDAQ: SGMT) has decreased by -13.95 when compared to last closing price of 6.02. Despite this, the company has experienced a -16.32% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-14 that Sagimet Biosciences Inc.’s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024. The global acne treatment market size is projected to grow from $17.48 billion by 2032. Results from phase 3 study by partner Ascletis, using denifanstat for treatment of patients with Acne Vulgaris, expected by Q2 of 2025.
SGMT’s Market Performance
Sagimet Biosciences Inc (SGMT) has seen a -16.32% fall in stock performance for the week, with a -5.13% decline in the past month and a 88.36% surge in the past quarter. The volatility ratio for the week is 10.76%, and the volatility levels for the past 30 days are at 9.72% for SGMT. The simple moving average for the last 20 days is -8.81% for SGMT stock, with a simple moving average of 13.94% for the last 200 days.
Analysts’ Opinion of SGMT
Many brokerage firms have already submitted their reports for SGMT stocks, with UBS repeating the rating for SGMT by listing it as a “Buy.” The predicted price for SGMT in the upcoming period, according to UBS is $12 based on the research report published on November 12, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see SGMT reach a price target of $6, previously predicting the price at $23. The rating they have provided for SGMT stocks is “Neutral” according to the report published on June 28th, 2024.
H.C. Wainwright gave a rating of “Buy” to SGMT, setting the target price at $32 in the report published on May 02nd of the current year.
SGMT Trading at 15.61% from the 50-Day Moving Average
After a stumble in the market that brought SGMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.99% of loss for the given period.
Volatility was left at 9.72%, however, over the last 30 days, the volatility rate increased by 10.76%, as shares sank -4.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +94.01% upper at present.
During the last 5 trading sessions, SGMT fell by -16.32%, which changed the moving average for the period of 200-days by -45.36% in comparison to the 20-day moving average, which settled at $5.68. In addition, Sagimet Biosciences Inc saw -4.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMT starting from Kemble George, who sale 23,625 shares at the price of $3.17 back on Jul 23 ’24. After this action, Kemble George now owns 118,693 shares of Sagimet Biosciences Inc, valued at $74,830 using the latest closing price.
Martins Eduardo Bruno, the Chief Medical Officer of Sagimet Biosciences Inc, sale 8,357 shares at $3.10 during a trade that took place back on Jul 19 ’24, which means that Martins Eduardo Bruno is holding 81,213 shares at $25,910 based on the most recent closing price.
Stock Fundamentals for SGMT
The total capital return value is set at -0.27. Equity return is now at value -29.32, with -27.79 for asset returns.
Based on Sagimet Biosciences Inc (SGMT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -331.84.
Currently, EBITDA for the company is -30.74 million with net debt to EBITDA at 2.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.11.
Conclusion
To sum up, Sagimet Biosciences Inc (SGMT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
